The HCPLive diabetic macular edema page is a comprehensive resource for clinical news and insights on DME. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for the leading cause of blindness, and more.
May 20th 2024
On May 20, 2024, the FDA announced the approval of 2 products as interchangeable biosimilars to aflibercept—the first products to receive such a designation from the FDA.
Retinal Thinning May Be Linked to Vascular Alterations in AMD Patients
August 8th 2018Recent research suggests that reticular pseudodrusen may be associated with the progression of early AMD to GA. Although an association has been theorized between pseudodrusen and AMD, researchers remain unclear on the pathogenesis of reticular pseudodrusen.
DRIL Presence Predictive of VA Improvement in Patients with Macular Edema, RVO
Amy S. Babicuh, MD, noted that “while DRIL is not the biomarker, it is certainly useful in conjunction with other information, and should prompt continued treatment with anti-VEGF agents when it is present.”
Diabetic Retinopathy Telemedicine Screening Could Greatly Benefit Underserved Populations
July 23rd 2018Telemedicine screenings provided by a primary care office in an urbanized setting over 2 years showed patients had an 81.9% compliance capture rate—a significant improvement from previous studies in the same field.
Real-World Analysis Supports More Frequent Anti-VEGF Dosing for First-Year nAMD
July 21st 2018Researchers found that, contrary to popular opinion, about 80% of patients are receiving at least 7 dosing regimens of anti-VEGF in their first year of treatment, and that frequency has been proven to improve visual acuity.